A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Toll-like receptor (TLR) mediated recognition of pathogen associated molecular patterns allows the immune system to rapidly respond to a pathogenic insult. The "danger context" elicited by TLR agonists allows an initially non-immunogenic antigen to become immunogenic. This ability to alter environment is highly relevant in tumor immunity, since it is inherently difficult for the immune system to recognize host-derived tumors as immunogenic. However, immune cells may have encountered certain TLR ligands associated with tumor development, yet the endogenous stimulation is typically not sufficient to induce spontaneous tumor rejection. Of special interest are TLR5 agonists, because there are no endogenous ligands that bind TLR5. CBLB502 is a pharmacologically optimized TLR5 agonist derived from Salmonella enterica flagellin. We examined the effect of CBLB502 on tumor immunity using two syngeneic lymphoma models, both of which do not express TLR5, and thus do not directly respond to CBLB502. Upon challenge with the T-cell lymphoma RMAS, CBLB502 treatment after tumor inoculation protects C57BL/6 mice from death caused by tumor growth. This protective effect is both natural killer (NK) cell- and perforin-dependent. In addition, CBLB502 stimulates clearance of the B-cell lymphoma A20 in BALB/c mice in a CD8(+) T cell-dependent fashion. Analysis on the cellular level via ImageStream flow cytometry reveals that CD11b(+) and CD11c(+) cells, but neither NK nor T cells, directly respond to CBLB502 as determined by NFκB nuclear translocation. Our findings demonstrate that CBLB502 stimulates a robust antitumor response by directly activating TLR5-expressing accessory immune cells, which in turn activate cytotoxic lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Cited by
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
Bacterial flagellin—a potent immunomodulatory agent
Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C., & Lee, J. H. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.172 · Cited by 387
Lauté-Caly, D. L., Raftis, E. J., Cowie, P., Hennessy, E., Holt, A., Panzica, D. A., Sparre, C., Minter, B., Stroobach, E., & Mulder, I. E. (2019) · Scientific Reports · doi:10.1038/s41598-018-36926-8 · Cited by 67
Shatz, M., Shats, I., Menendez, D., & Resnick, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4435 · Cited by 29
Metadata
- Authors
- Leigh, N. D., Bian, G., Ding, X., Liu, H., Aygun-Sunar, S., Burdelya, L. G., Gudkov, A. V., & Cao, X.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-14
- Volume
- 9
- Issue
- 1
- Pages
- e85587
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1966830804
- Cited by
- 62
- References
- 1
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity. https://app.cochat.ai/papers/10.1371/journal.pone.0085587
- The paper
- Leigh, N. D., Bian, G., Ding, X., Liu, H., Aygun-Sunar, S., Burdelya, L. G., Gudkov, A. V., & Cao, X. (2014). A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity. PLoS ONE. https://doi.org/10.1371/journal.pone.0085587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.